Back to top
more

Catalyst Pharmaceuticals (CPRX)

(Delayed Data from NSDQ)

$31.38 USD

31.38
3,352,548

-0.02 (-0.06%)

Updated Jun 18, 2026 03:59 PM ET

After-Market: $31.38 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Catalyst (CPRX) Focused on Development of Pipeline Candidates

by Zacks Equity Research

Catalyst Pharmaceuticals, Inc. (CPRX) focuses on the development of its pipeline candidates Firdapse and CPP-115.

    Zacks Equity Research

    Catalyst (CPRX) Posts Narrower than Expected Loss in Q2

    by Zacks Equity Research

    Catalyst Pharmaceuticals, Inc. (CPRX) reported narrower than expected loss in Q2 and is focused on the development of its pipeline candidate Firdapse.

      Zacks Equity Research

      What's in Store for Catalyst (CPRX) This Earnings Season?

      by Zacks Equity Research

      With Catalyst Pharmaceuticals, Inc. (CPRX) not having any marketed product in its portfolio, its focus at the Q2 conference call will be on the progress of its pipeline candidates, Firdapse, CPP-115 and CPP-109.

        Zacks Equity Research

        Catalyst (CPRX) Shows Strength: Stock Adds 9.6% in Session

        by Zacks Equity Research

        Catalyst Pharmaceuticals, Inc. (CPRX) shares rose around 10% in the last trading session.

          Zacks Equity Research

          Why is Catalyst Pharmaceuticals' Stock Up 160% this Year?

          by Zacks Equity Research

          Shares of Catalyst Pharmaceuticals, Inc. (CPRX) have soared 161% this year so far, massively outperforming the Zacks classified Medical Drugs industry's gain of 10.2%.

            Zacks Equity Research

            Why Is Catalyst Pharmaceuticals (CPRX) Up 25.5% Since the Last Earnings Report?

            by Zacks Equity Research

            Catalyst Pharmaceuticals (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              Zacks Equity Research

              Catalyst Pharmaceuticals (CPRX) Shares March Higher, Can It Continue?

              by Zacks Equity Research

              As of late, it has definitely been a great time to be an investor in Catalyst Pharmaceuticals Inc (CPRX).

                Zacks Equity Research

                Catalyst Pharmaceuticals Focuses on Development of Firdapse

                by Zacks Equity Research

                We issued an updated report on Catalyst Pharmaceuticals, Inc. (CPRX) on May 22.

                  Zacks Equity Research

                  Catalyst Pharmaceuticals (CPRX) Posts Loss as Expected in Q1

                  by Zacks Equity Research

                  Catalyst Pharmaceuticals, Inc. (CPRX) reported a loss of 6 cents per share in the first quarter of 2017, in line with the Zacks Consensus Estimate but narrower than the loss of 7 cents in the year-ago quarter.

                    Zacks Equity Research

                    What's in Store for Catalyst (CPRX) Stock in Q1 Earnings?

                    by Zacks Equity Research

                    Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report first-quarter 2017 results on May 11.